• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precigen Reports Full Year 2024 Financial Results and Business Updates

    3/19/25 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email
    • FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025
    • Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory Medicine
    • PRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoff
    • Company continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch
    • Company ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending its cash runway into 2026, beyond potential 2025 commercial launch of PRGN-2012

    GERMANTOWN, Md., March 19, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2024 financial results and business updates.

    Precigen Logo (PRNewsfoto/Precigen, Inc.)

    "Last year, we achieved several milestones on our path to potentially bring our innovative PRGN-2012 therapy to RRP patients, including presentation of groundbreaking pivotal data and BLA submission to the FDA. Through prioritizing our portfolio and financing activities, we strengthened our financial position, enabling ongoing commercial and manufacturing readiness efforts for PRGN-2012 in anticipation of a potential 2025 launch. Our commercial organization has been working to scale up quickly, right-sizing the organization to rapidly capitalize on the immense demand from patients and treating physicians for a new treatment paradigm that may finally address the underlying cause of the disease," said Helen Sabzevari, PhD, President and CEO of Precigen. "Already this year, our BLA for PRGN-2012 received priority review from the FDA with an August 2025 PDUFA action date, bringing us a step closer to launching the first and only FDA-approved treatment to the approximately 27,000 adult RRP patients in the US. FDA approval for PRGN-2012 would fundamentally change Precigen, enabling the transition from clinical to commercial stage with the real and imminent potential to begin realizing product sales this year and providing financial tailwinds to enable potential expansion of PRGN-2012 to new indications and geographical markets." 

    "As a result of the preferred stock offering and sale of intellectual property and related royalty rights for a non-core asset, we extended our cash runway into 2026, beyond the potential commercial launch of PRGN-2012 this year. We are preparing for the transition to a commercial stage company and the potential to add product-related revenue," said Harry Thomasian Jr., CFO of Precigen.

    Key Program Highlights

    PRGN-2012 (nonproprietary name: zopapogene imadenovec†) AdenoVerse® Gene Therapy in RRP 

    PRGN-2012 is an investigational off-the-shelf AdenoVerse gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus (HPV) 6 or HPV 11 for the treatment of recurrent respiratory papillomatosis (RRP). PRGN-2012 received Breakthrough Therapy Designation, Orphan Drug Designation, and an accelerated approval pathway from the FDA, and Orphan Drug Designation from the European Commission.

    • In February 2025, the US Food and Drug Administration (FDA) accepted the company's biologics license application (BLA) for PRGN-2012, and granted priority review to the BLA with a Prescription Drug User Fee Act (PDUFA) target action date set for August 27, 2025. The FDA has indicated that they are not currently planning to hold an advisory committee meeting to discuss the BLA.
    • Results from the pivotal clinical study of PRGN-2012 for the treatment of RRP were presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting in a late-breaking oral presentation titled, "PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients" and published in The Lancet Respiratory Medicine.
      • Pivotal study successfully met its primary safety and pre-specified primary efficacy endpoints.
      • PRGN-2012 was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2.
      • 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012. Complete Responses have been durable beyond 12 months with median duration of follow up of 24 months, with some complete responders surgery-free beyond three years as of the August 28, 2024 data cutoff.
      • 86% of patients (30 out of 35) had a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior to treatment; RRP surgeries reduced from a median of 4 (range: 3-10) pre-treatment to 0 (range: 0-7) post-treatment.
      • PRGN-2012 treatment induced HPV 6/11-specific T cell responses in RRP patients with a significantly greater expansion of peripheral HPV-specific T cells in responders compared with non-responders.
      • PRGN-2012 significantly (p < 0.0001) improved anatomical Derkay scores and VHI-10 scores in complete responders.
    • Patient enrollment continues to advance in the confirmatory clinical trial of PRGN-2012 in accordance with the guidance from the FDA to initiate the study prior to submission of the BLA.
    • The Company continues to rapidly advance its commercial and manufacturing readiness campaign in anticipation of a potential launch in 2025.
    • Based on recently updated internal analysis derived from review of claims data, the market opportunity for PRGN-2012 in RRP is estimated to be approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US.

    PRGN-2009 AdenoVerse® Gene Therapy in HPV-associated cancers

    PRGN-2009 is an investigational off-the-shelf AdenoVerse gene therapy designed to activate the immune system to recognize and target HPV-associated cancers.

    • PRGN-2009 Phase 2 clinical trials under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) in recurrent/metastatic cervical cancer and in newly diagnosed HPV-associated oropharyngeal cancer are ongoing.

    PRGN-3006 UltraCAR-T® in AML and MDS

    PRGN-3006 is an investigational multigenic, autologous chimeric antigen receptor T cell (CAR-T) therapy engineered to simultaneously express a CAR specifically targeting CD33, membrane bound IL-15 (mbIL15), and a safety/kill switch. PRGN-3006 has been granted Orphan Drug Designation in patients with acute myeloid leukemia (AML) and Fast Track Designation in patients with relapsed/refractory (r/r) AML by the FDA.

    • The Company has completed enrollment of the Phase 1b trial for PRGN-3006 in acute myeloid leukemia (AML), which received Fast Track designation from the FDA, and is preparing for an end of Phase 1b meeting with the FDA to discuss next steps.

    Financial Highlights

    • In December 2024, the Company raised $87.5 million, of which $79.0 million was from a private placement offering of convertible preferred stock, and an additional $8.5 million was from the sale of certain intellectual property and royalty rights related to a non-core asset.
    • By year's end 2024, cash, cash equivalents, and investments totaled $97.9 million.

    Full Year 2024 Financial Results Compared to Prior Year Period

    Total revenues decreased $2.3 million, or 37%, and cost of products and services decreased $1.8 million or 30% compared to the year ended December 31, 2023. These decreases were primarily related to reductions in product and service volumes at Exemplar.

    Research and development expenses increased $4.5 million, or 9%, compared to the year ended December 31, 2023. This increase was primarily the result of $3.1 million of increased costs associated with the initiation of the PRGN-2012 confirmatory clinical trial, increased drug manufacturing material costs related to PRGN-2012 for potential commercial use, and professional fees incurred in conjunction with the Company's completed BLA submission and commercial readiness planning as well as the design and implementation of our manufacturing facility. Additionally, employee-related expenses rose by $3.0 million primarily due to severance charges incurred as a result of the Precigen workforce reduction in 2024 and the suspension of ActoBio's operations. These increases were partially offset by a $1.9 million reduction in depreciation and amortization expense as a result of the impairment of noncurrent assets related to the suspension of ActoBio's operations during the second quarter of 2024 as well as a reduction in clinical study expenses associated with programs that were deprioritized during the third quarter of 2024.

    SG&A expenses increased $0.9 million, or 2%, compared to the year ended December 31, 2023. As a result of the Company's increased focus on PRGN-2012, commercial readiness costs increased in 2024 compared to the prior year. In addition, the second and third quarters of 2024 included higher severance costs associated with the suspension of ActoBio's operations and the Precigen workforce reduction. These increases were partially offset by a decrease in stock compensation and insurance rates in 2024 compared to the same period in 2023.

    The Company recorded a $5.8 million impairment charge in the fourth quarter of 2024 related to its Exemplar subsidiary as a result of the Company's annual goodwill impairment test. Also, in conjunction with the suspension of ActoBio's operations, the Company recorded $34.5 million of impairment charges related to goodwill ($1.6 million) and other noncurrent assets ($32.9 million) in the second quarter of 2024.

    Total other income, net, increased $3.6 million, or 106% compared to the year ended December 31, 2023. This increase was primarily derived from an $8.5 million gain on the sale of intellectual property rights and royalty rights related to a non-core asset in December 2024 as well as a $0.5 million reduction in interest expense due to the final retirement of the Company Convertible Notes in the second quarter of 2023. This increase was partially offset by a reclassification of cumulative translation losses of $2.9 million, which resulted from the final closing of the ActoBio facilities in the third quarter of 2024, as well as a reduction of $1.8 million in interest income compared to the same period in 2023.

    Net loss was $126.2 million, or $(0.47) per basic and diluted share, compared to net loss of $95.9 million, or $(0.39) per basic and diluted share, in year ended December 31, 2023.

    Precigen: Advancing Medicine with Precision®

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

    Trademarks

    Precigen, UltraCAR-T, UltraPorator, AdenoVerse, UltraVector and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

    Cautionary Statement Regarding Forward-Looking Statements

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Investor Contact:

    Steven M. Harasym

    Tel: +1 (301) 556-9850

    [email protected]

    Media Contacts:

    Donelle M. Gregory

    [email protected]

    †zopapogene imadenovec is the nonproprietary name for the investigational therapeutic known as PRGN-2012. Zopapogene imadenovec has not been approved by any health authority in any country for any indication.

     

    Precigen, Inc. and Subsidiaries

    Consolidated Balance Sheets

    (Unaudited)



    (Amounts in thousands)

    December 31, 2024

    December 31, 2023

    Assets





    Current assets





        Cash and cash equivalents

    $                           29,517

    $                                    7,578

        Short-term investments

    68,393

    55,277

        Receivables





            Trade, net

    926

    902

            Other

    237

    673

        Prepaid expenses and other

    3,341

    4,325

                    Total current assets

    102,414

    68,755

        Property, plant and equipment, net

    13,831

    7,111

        Intangible assets, net

    4,455

    40,701

        Goodwill

    19,139

    26,612

        Right-of-use assets

    5,056

    7,097

        Other assets

    371

    767

                    Total assets

    $                         145,266

    $                                151,043

    Liabilities, Mezzanine Equity and Shareholders' Equity





    Current liabilities





        Accounts payable

    $                              3,531

    $                                    1,726

        Accrued compensation and benefits

    8,417

    8,250

        Other accrued liabilities

    4,812

    6,223

        Indemnification Accrual

    3,213

    5,075

        Deferred revenue

    589

    509

        Current portion of lease liabilities

    956

    1,202

                    Total current liabilities

    21,518

    22,985

        Deferred revenue, net of current portion

    1,934

    1,818

        Lease liabilities, net of current portion

    4,546

    5,895

        Deferred tax liabilities

    -

    1,847

        Warrant liabilities

    50,537

    -

                    Total liabilities

    78,535

    32,545

    Mezzanine Equity





                    Series A Preferred Stock

    28,218

    -

    Shareholders' equity





        Common stock

    -

    -

        Additional paid-in capital

    2,129,207

    2,084,916

        Accumulated deficit

    (2,090,706)

    (1,964,471)

        Accumulated other comprehensive income (loss)

    12

    (1,947)

                    Total shareholders' equity

    38,513

    118,498

                    Total liabilities, mezzanine equity and shareholders' equity

    $                         145,266

    $                                151,043

     

    Precigen, Inc. and Subsidiaries

    Consolidated Statements of Operations 

    (Unaudited)





    Year ended

    (Amounts in thousands, except share and per share data)                                   

    December 31, 2024

    December 31, 2023

    Revenues





      Collaboration and licensing revenues

    $                        -

    $                      75

    Product revenues

    422

    840

    Service revenues

    3,470

    5,301

    Other revenues

    33

    9

    Total revenues

    3,925

    6,225

    Operating Expenses





    Cost of products and services

    4,267

    6,119

    Research and development

    53,070

    48,614

    Selling, general and administrative

    41,293

    40,415

    Impairment of goodwill

    7,409

    10,390

    Impairment of other noncurrent assets

    32,915

    445

    Total operating expenses

    138,954

    105,983

    Operating loss

    (135,029)

    (99,758)

    Other Income (Expense), Net





    Interest expense

    (6)

    (468)

    Interest income

    1,418

    3,237

    Other income, net

    5,589

    627

    Total other income, net

    7,001

    3,396

                 Loss before income taxes

    (128,028)

    (96,362)

    Income tax benefit

    1,793

    458

                 Net loss

    $          (126,235)

    $             (95,904)

    Net Loss per share





                 Net loss per share, basic and diluted

    $                 (0.47)

    $                 (0.39)

    Weighted average shares outstanding, basic and diluted

    267,727,426

    244,536,221

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-reports-full-year-2024-financial-results-and-business-updates-302406034.html

    SOURCE Precigen, Inc.

    Get the next $PGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, IP Affairs Perez Jeffrey Thomas bought $50,000 worth of shares (58,823 units at $0.85), increasing direct ownership by 9% to 743,097 units (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 5:09:47 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kirk Randal J bought $19,999,999 worth of shares (23,529,411 units at $0.85) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      8/13/24 4:15:11 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kirk Randal J bought $136,327 worth of shares (96,686 units at $1.41) (SEC Form 4)

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      12/29/23 7:30:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Financials

    Live finance-specific insights

    See more
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

      GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

      12/27/24 9:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

      GERMANTOWN, Md., Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357

      8/9/24 8:00:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Precigen Inc.

      PRE 14A - PRECIGEN, INC. (0001356090) (Filer)

      5/6/25 4:15:29 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Precigen Inc.

      10-K/A - PRECIGEN, INC. (0001356090) (Filer)

      4/28/25 5:23:16 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Precigen Inc.

      10-K - PRECIGEN, INC. (0001356090) (Filer)

      3/19/25 4:30:08 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Precigen Inc.

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      8/13/24 4:05:10 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

      SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

      5/3/24 8:01:15 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

      SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

      2/27/24 1:48:40 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Tennant Phil

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:06:44 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Shah Rutul R

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:52 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Lehr Donald P.

      4 - PRECIGEN, INC. (0001356090) (Issuer)

      4/18/25 5:02:35 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precigen downgraded by JP Morgan

      JP Morgan downgraded Precigen from Neutral to Underweight

      3/22/24 7:52:12 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Precigen

      JP Morgan initiated coverage of Precigen with a rating of Neutral

      5/23/23 7:32:58 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Precigen with a new price target

      Cantor Fitzgerald initiated coverage of Precigen with a rating of Overweight and set a new price target of $7.00

      11/18/22 7:56:19 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Reports Full Year 2024 Financial Results and Business Updates

      FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025Results from pivotal clinical study of PRGN-2012 were published in The Lancet Respiratory MedicinePRGN-2012 treatment demonstrated durable complete responses with median duration of response of two years, with some complete responders surgery-free beyond three years as of August 28, 2024 data cutoffCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launchCompany ended 2024 with $97.9 million in cash, cash equivalents, and investments, extending i

      3/19/25 4:05:00 PM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

      GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

      3/13/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

      – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

      4/16/25 8:05:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

      –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

      7/23/24 8:01:00 AM ET
      $PGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care